secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001213900-25-012870
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio completes Phase I dose cohort for INKmune in mCRPC, opens Phase II
-----------------------------------------------------------------------------

- Third and highest dose cohort of Phase I completed; no safety issues found.
- Scientific Review Committee unanimously voted to open all Phase II cohorts of CaRePC trial.
- Low dose cohort showed immunologic effects; higher dose cohorts to assess therapeutic benefits.
- CEO R.J. Tesi noted INKmune given in outpatient setting with exemplary safety profile.
- CSO Mark Lowdell invited to speak at 10th Annual Innate Killer Summit on March 4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/0001213900-25-012870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-012870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer